Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate HighlightsGlobeNewsWire • 03/26/25
Nkarta (NKTX) Loses -33.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 03/20/25
Nkarta (NKTX) Loses -32.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 03/19/25
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2GlobeNewsWire • 12/05/24
Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL PatientsSeeking Alpha • 08/14/24
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate HighlightsGlobeNewsWire • 08/14/24
Nkarta Reports Second Quarter 2024 Financial Results and Corporate HighlightsGlobeNewsWire • 08/13/24
Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus ErythematosusGlobeNewsWire • 07/24/24
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune IndicationsGlobeNewsWire • 06/27/24
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of DirectorsGlobeNewsWire • 06/13/24
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street's RadarInvestorPlace • 05/07/24